According to Paratek Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $0.16 B. In 2022 the company made a revenue of $0.15 B an increase over the years 2021 revenue that were of $0.12 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.16 B | 11.24% |
2022 | $0.15 B | 24.67% |
2021 | $0.12 B | 177.94% |
2020 | $43.51 M | 163.04% |
2019 | $16.54 M | -3.35% |
2018 | $17.11 M | 35.68% |
2017 | $12.61 M | 43403.45% |
2016 | $0.02 M | |
2015 | N/A | -100% |
2014 | $4.34 M | 148.54% |
2013 | $1.74 M | -84.16% |
2012 | $11.02 M | -44.01% |
2011 | $19.69 M | 57.55% |
2010 | $12.5 M | 140.02% |
2009 | $5.2 M | -91.41% |
2008 | $60.62 M | |
2005 | $0.05 M | -95% |
2004 | $1.12 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Ultragenyx RARE | $0.43 B | 158.88% | ๐บ๐ธ USA |
Spectrum Pharmaceuticals
SPPI | $25.72 M | -84.66% | ๐บ๐ธ USA |
Agenus
AGEN | $0.15 B | -6.81% | ๐บ๐ธ USA |